The focus is on the business as a contract manufacturer for active ingredients, which has become a strategic option for many pharmaceutical companies in order to flexibly scale development and production. With this investment, Evonik is not only creating additional capacity, but also around 50 new jobs and at the same time strengthening the site's role as a European centre for biotechnological production. The expansion is part of a long-term strategy. Evonik had already set up a plant for rhamnolipids here in 2022, thus transferring a new generation of sustainable biosurfactants to industrial production. Today, the site is considered one of the most important hubs for fermentation-based technologies in the Group. These processes enable the production of complex molecules under comparatively resource-efficient conditions and are seen as the key to the next wave of pharmaceutical innovations. For Evonik, the development is more than just an expansion of capacity. The investment strengthens Evonik in the global competition for biotechnological value creation. As demand for specialised active ingredients continues to rise, the Group is positioning itself as a reliable partner for life science companies that rely on scalable and sustainable production solutions.
Press release of "Evonik Industries AG" dated 22 April 2026